Skip to main content

Detail

Oliver Langer
Assoc.-Prof. PD Mag. Dr. Oliver LangerHead Translational Imaging Research

Department of Clinical Pharmacology
Position: Associate Professor

ORCID: 0000-0002-4048-5781
T +43 1 40400-29810
oliver.langer@meduniwien.ac.at

Further Information

Keywords

ATP-Binding Cassette Transporters; Blood-Brain Barrier; Central Nervous System; Drug Carriers; Drug Development; Drug Interactions; Kidney; Liver; Lung; Membrane Transport Proteins; Nuclear Medicine; Pharmacokinetics; Pharmacology, Clinical; Positron-Emission Tomography; Radionuclide Imaging; Tissue Distribution

Research group(s)

Research interests

In my research I use positron emission tomography (PET) imaging with radiolabeled drug molecules to assess factors governing the tissue distribution and excretion of drugs in health and disease with a special emphasis on the action of membrane transporters belonging to the ATP-binding cassette (ABC) and solute carrier (SLC) families. My research covers preclinical and clinical PET studies in healthy rodents, rodent disease models (Alzheimer's disease, epilepsy), healthy human volunteers and patients. I am also interested in the development of new PET imaging protocols to measure the activity of ABC and SLC transporters in different organs (brain, eye, liver, kidneys, lungs) and in the development of strategies to enhance the brain distribution of moleculary targeted anticancer drugs.

Techniques, methods & infrastructure

Preclinical and clinical positron emission tomography (PET); radiotracer development; radiochemistry; carbon-11 and fluorine-18 labelling; pharmacokinetic modeling; quantitative image analysis; in vitro transport experiments; autoradiography; metabolite analysis

Grants

Selected publications

  1. Bauer, M. et al., 2020. Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects. Clinical Pharmacology & Therapeutics. Available at: http://dx.doi.org/10.1002/cpt.2052.
  2. Mairinger, S. et al., 2020. Assessing the Activity of Multidrug Resistance–Associated Protein 1 at the Lung Epithelial Barrier. Journal of Nuclear Medicine, 61(11), pp.1650–1657. Available at: http://dx.doi.org/10.2967/jnumed.120.244038.
  3. Zoufal, V. et al., 2019. Imaging P-Glycoprotein Induction at the Blood–Brain Barrier of a β-Amyloidosis Mouse Model with 11C-Metoclopramide PET. Journal of Nuclear Medicine, 61(7), pp.1050–1057. Available at: http://dx.doi.org/10.2967/jnumed.119.237198.
  4. Bauer, M. et al., 2017. Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. Clinical Pharmacology & Therapeutics, 104(1), pp.139–147. Available at: http://dx.doi.org/10.1002/cpt.888.
  5. Bauer, M. et al., 2016. Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood–Brain Barrier. Clinical Pharmacology & Therapeutics, 100(2), pp.131–141. Available at: http://dx.doi.org/10.1002/cpt.362.